Stephen G. Machatha, Ph.D., has served as our Chief Development Officer since January 2021. He is responsible for the CMC Operations, Non-Clinical Development, Regulatory Affairs, Clinical Operations, and Intellectual Property Management. Dr. Machatha has 20 years of experience in the pharmaceutical industry, spanning multiple functional and therapeutic areas. Dr. Machatha joined Aldeyra in January 2016 as Vice President of Chemistry Manufacturing and Controls, was later appointed as Senior Vice President of Technical Operations in January 2019. Prior to joining Aldeyra, Dr. Machatha held scientific and product development roles of increasing responsibilities at Synageva Biopharmaceuticals (Acquired by Alexion Pharmaceuticals), Cubist Pharmaceuticals (Acquired by Merck & Co.), and CyDex Pharmaceuticals (Acquired by Ligand Pharmaceuticals). Dr. Machatha played an instrumental role in the development and subsequent approvals of KANUMA® (sebelipase alfa), NEXTERONE® (Amiodarone HCL), Evomela® (High Dose Melphalan HCL), and SESQUIENT® (Fosphenytoin Sodium). Dr. Machatha attended the University of Arizona, where he received a Ph.D. in Pharmaceutical Sciences, an M.A. in Chemistry, and a B.Sc. in Chemistry.
Back to Leadership Team & Board of Directors